RESUMO
A case is presented of painful priapism of the clitoris lasting 3 days, with a strong temporal association with the administration of nefazodone hydrochloride. Priapism has been described as a rare side-effect of drugs with high alpha1-adrenergic blocking potential. However, the alpha1-adrenergic blocking potential of nefazodone is moderate. Drug-induced clitoral priapism has been described for citalopram, bromocriptine, fluoxetine and trazodone combined with fluoxetine. To our knowledge, this is the first report in the literature about priapism of the clitoris associated with nefazodone.
Assuntos
Antidepressivos de Segunda Geração/efeitos adversos , Clitóris/efeitos dos fármacos , Triazóis/efeitos adversos , Doenças Vaginais/induzido quimicamente , Antidepressivos de Segunda Geração/uso terapêutico , Transtorno Depressivo/complicações , Transtorno Depressivo/tratamento farmacológico , Feminino , Humanos , Pessoa de Meia-Idade , Piperazinas , Triazóis/uso terapêutico , Doenças Vaginais/patologiaRESUMO
Hairs are produced in hair follicles that have a cyclic activity. The cycles that normal hair follicles go through are the metabolically active anagen phase, the catagen transitional phase and the resting telogen phase. Loss of more than 120 hairs daily is called alopecia. Drugs typically cause a diffuse, reversible alopecia by influencing one of the cycles that hair follicles go through. Because hair loss can have many causes, a causal relationship between a suspected drug and hair loss may be hard to prove. The principal categories of drugs that may cause alopecia listed in the literature are cytostatics, anticoagulants, interferons, tretinoid derivatives and lithium carbonate. The Netherlands Pharmacovigilance Foundation LAREB has received reports of alopecia as side effect of antimalarials, beta-receptor blocking agents, sex hormones, ACE inhibitors, angiotensin II antagonists and anticoagulants.
Assuntos
Alopecia/induzido quimicamente , Corticosteroides/efeitos adversos , Antagonistas Adrenérgicos beta/efeitos adversos , Sistemas de Notificação de Reações Adversas a Medicamentos , Idoso , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Anti-Inflamatórios não Esteroides/efeitos adversos , Anticolesterolemiantes/efeitos adversos , Anticoagulantes/efeitos adversos , Anticonvulsivantes/efeitos adversos , Antifúngicos/efeitos adversos , Antimaláricos/efeitos adversos , Feminino , Hormônios Esteroides Gonadais/efeitos adversos , Humanos , Masculino , Pessoa de Meia-Idade , Países BaixosRESUMO
The Netherlands Pharmacovigilance Foundation LAREB received five case reports concerning transient impairment of micturition or urinary retention, suspected to be induced by tramadol. In all patients--three women and two men--the symptoms occurred in temporal association with the use of tramadol and promptly recovered after stopping of the drug. Tramadol was taken orally in doses within the recommended therapeutic range (150 mg or less daily). Disturbance of micturition is not mentioned as a side-effect in the summary of product characteristics of Tramal 50 and 100. Tramadol is an opioid agonist, however, and morphine is known to increase the tonus of the bladder sphincter and to cause urinary retention.
